Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.

Mikhail Naum KosiborodOtavio BerwangerGary G KochFelipe MartinezOmar MukhtarSubodh VermaVijay ChopraAli JavaheriPhilip AmberySamvel B GasparyanJoan BuenconsejoC David SjöströmAnna Maria LangkildeJan OscarssonRussell Esterline

Published in: Diabetes, obesity & metabolism (2021)

DARE-19 will evaluate whether dapagliflozin can prevent COVID-19-related complications and all-cause mortality, or improve clinical recovery, and assess the safety profile of dapagliflozin in this patient population. Currently, DARE-19 is the first large randomized controlled trial investigating use of sodium-glucose cotransporter 2 inhibitors in patients with COVID-19.

Keyphrases

coronavirus disease
randomized controlled trial
respiratory failure
sars cov
study protocol
mechanical ventilation
case report
systematic review
intensive care unit
acute respiratory distress syndrome
respiratory syndrome coronavirus